Active Substance: desloratadine
Common Name: desloratadine
ATC Code: R06AX27
Marketing Authorisation Holder: Actavis Group PTC ehf
Active Substance: desloratadine
Authorisation Date: 2012-01-13
Therapeutic Area: Urticaria Rhinitis, Allergic, Seasonal Rhinitis, Allergic, Perennial
Pharmacotherapeutic Group: Antihistamines for systemic use
Treatment of allergic rhinitis and urticaria.
What is Desloratadine Actavis?
Desloratadine Actavis is a medicine containing the active substance desloratadine. It is available as tablets (5 mg).
Desloratadine Actavis is a ‘generic medicine’. This means that Desloratadine Actavis is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Aerius.
What is Desloratadine Actavis used for?
Desloratadine Actavis is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
The medicine can only be obtained with a prescription.
How is Desloratadine Actavis used?
The recommended dose for adults and adolescents (12 years of age and over) is 5 mg once a day.
How does Desloratadine Actavis work?
The active substance in Desloratadine Actavis, desloratadine, is an antihistamine. It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms, normally attaches itself. When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.
How has Desloratadine Actavis been studied?
Because Desloratadine Actavis is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Aerius. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
What are the benefits and risks of Desloratadine Actavis?
Because Desloratadine Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Why has Desloratadine Actavis been approved?
The CHMP concluded that, in accordance with EU requirements, Desloratadine Actavis has been shown to have comparable quality and to be bioequivalent to Aerius. Therefore, the CHMP’s view was that, as for Aerius, the benefit outweighs the identified risk. The Committee recommended that Desloratadine Actavis be given marketing authorisation.
Other information about Desloratadine Actavis
The European Commission granted a marketing authorisation valid throughout the European Union for Desloratadine Actavis on 13 January 2012.
For more information about treatment with Desloratadine Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.